Literature DB >> 16952495

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

Miki Nakajima1, Tatsuki Fukami, Hiroyuki Yamanaka, Eriko Higashi, Haruko Sakai, Ryoko Yoshida, Jun-Tack Kwon, Howard L McLeod, Tsuyoshi Yokoi.   

Abstract

Human cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine and is a possible modulator of nicotine addiction. Quantitative and qualitative differences in nicotine addiction have been observed between ethnic groups. However, there are few data on the ethnic influences of the CYP2A6-nicotine metabolism relationship, particularly with regard to black subjects. We determined the nicotine metabolism and CYP2A6 genotype in 176 white subjects and 160 black subjects, comparing them with our previous data from 209 Korean subjects and 92 Japanese subjects. Large interindividual differences were observed in the cotinine/nicotine ratios in plasma calculated as an index of nicotine metabolism in white subjects (range, 0.6-36.5) and in black subjects (range, 0.9-30.4). No ethnic difference in the metabolic ratio was observed among white subjects (mean, 7.2 +/- 5.0), black subjects (mean, 7.1 +/- 4.7), and Korean subjects (mean, 8.7 +/- 11.9), whereas Japanese subjects showed a significantly (P < .005) lower metabolic ratio (mean, 3.8 +/- 3.1) compared with the other populations. Women showed significantly (P < .05) higher metabolic ratios than men in the black population (8.0 +/- 5.3 versus 6.0 +/- 3.7). Obvious ethnic differences in the CYP2A6 alleles were observed among these 4 populations. The combined frequencies of the alleles lacking or showing reduced enzymatic activity (CYP2A6*2, CYP2A6*4, CYP2A6*5, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*17, CYP2A6*19, and CYP2A6*20) were 9.1%, 21.9%, 42.9%, and 50.5% in white, black, Korean, and Japanese subjects, respectively. These CYP2A6 alleles were associated with reduced nicotine metabolism. Among the homozygotes of CYP2A6*1, interindividual and ethnic differences in the metabolic ratio were still observed. Thus some factors other than genetic ones might also contribute to the interindividual and ethnic differences. This comprehensive study of 4 populations extends our understanding of nicotine metabolism and the impact of genetic polymorphisms of the CYP2A6 gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952495     DOI: 10.1016/j.clpt.2006.05.012

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  86 in total

1.  1,3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers.

Authors:  Sungshim Lani Park; Srikanth Kotapati; Lynne R Wilkens; Maarit Tiirikainen; Sharon E Murphy; Natalia Tretyakova; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11       Impact factor: 4.254

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

3.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

4.  CYP2A6 genetic variation and dexmedetomidine disposition.

Authors:  Utkarsh Kohli; Pratik Pandharipande; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; E Wesley Ely; Rachel F Tyndale; Leena Choi; C Michael Stein; Daniel Kurnik
Journal:  Eur J Clin Pharmacol       Date:  2012-01-21       Impact factor: 2.953

5.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

6.  Genotype frequency and F ST analysis of polymorphisms in immunoregulatory genes in Chinese and Caucasian populations.

Authors:  Qing Lan; Min Shen; Dino Garcia-Rossi; Stephen Chanock; Tongzhang Zheng; Sonja I Berndt; Vinita Puri; Guilan Li; Xingzhou He; Robert Welch; Shelia H Zahm; Luoping Zhang; Yawei Zhang; Martyn Smith; Sophia S Wang; Brian C-H Chiu; Martha Linet; Richard Hayes; Nathaniel Rothman; Meredith Yeager
Journal:  Immunogenetics       Date:  2007-10-16       Impact factor: 2.846

7.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

8.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

9.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

10.  Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.

Authors:  Yu Hong Li; Hui Yan Luo; Feng Hua Wang; Zhi Qiang Wang; Miao Zhen Qiu; Yan Xia Shi; Xiao Juan Xiang; Xiao Qing Chen; You Jian He; Rui Hua Xu
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.